Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 15/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 15/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149567 | 1.00 | AR (0.50) | ARAVPR2AVPR1APTGESSLC6A2 | |
| SCHEMBL4148811 | 0.87 | AR (0.50) | ARAVPR2AVPR1APTGES | |
| SCHEMBL4134415 | 0.87 | AR (0.50) | ARAVPR2AVPR1APTGES | |
| SCHEMBL4134411 | 0.87 | AR (0.50) | ARAVPR2AVPR1APTGES | |
| SCHEMBL4139112 | 0.86 | AR (0.33) | ARAVPR2AVPR1A | |
| SCHEMBL4139051 | 0.86 | AR (0.65) | AR | |
| SCHEMBL9885147 | 0.85 | AR (0.53) | ARAVPR2AVPR1A | |
| SCHEMBL4134427 | 0.85 | AR (0.53) | ARAVPR2AVPR1A | |
| SCHEMBL4134431 | 0.85 | AR (0.53) | ARAVPR2AVPR1A | |
| SCHEMBL4133996 | 0.84 | AR (0.51) | ARAVPR2AVPR1ASLC6A2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | claimed |
| US-8193357-B2 | Androgen receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | claimed |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | US | claimed |
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-01-29 | — | — | US | claimed |
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885AVPR2 462/4885AVPR1A 391/4885 |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885AVPR2 462/4885AVPR1A 391/4885 |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885AVPR2 462/4885AVPR1A 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.